US Funding Retreat Challenges Zimbabwe's HIV Drug Access

Zimbabwe's rollout of lenacapavir, a twice-yearly HIV prevention shot, faces challenges as US funding retreats. This shift in international aid impacts access for vulnerable populations, particularly those who rely on the drug as an easier alternative to daily oral pills. Advocates for continued aid highlight concerns that funding cuts could precipitate a reversal in HIV prevention gains. Conversely, some observers emphasize the necessity of domestic resource mobilization to sustain such programs. The impending withdrawal of US support could significantly limit access for individuals currently receiving or awaiting treatment. Bottom Line: US funding changes create friction for Zimbabwe's HIV prevention strategy and drug access, prompting resource re-evaluation.